Core Viewpoint - Rosen Law Firm is reminding investors who purchased BioAge Labs, Inc. stock during its IPO on September 26, 2024, of the March 10, 2025 deadline to become lead plaintiffs in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased BioAge stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court by March 10, 2025, to serve as lead plaintiff [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Background - The lawsuit alleges that BioAge misrepresented the safety and efficacy of its lead product candidate, azelaprag, in connection with the STRIDES clinical trial, which was expected to yield topline results in 2025 [5]. - BioAge discontinued the STRIDES Phase 2 study after subjects exhibited elevated liver enzyme levels, indicating potential organ damage, which was not disclosed in prior trials [6].
BIOA DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages BioAge Labs, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 10 Deadline in Securities Class Action – BIOA